The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression : a prospective, case-control study
BACKGROUND: This study examined the relationship between levels of the chemokines CXCL9, CXCL10, CXCL11, and CXCR3 and mortality in patients with COVID-19.
METHODS: A total of 71 patients hospitalized with COVID-19 and 35 health workers with no symptoms and negative SARS-CoV-2 PCR results were included in the study. CXCL9, CXCL10, CXCL11, and CXCR3 levels were measured in blood samples using enzyme-linked immunosorbent assays. Participants were divided into three groups: healthy individuals, patients with mild to moderate pneumonia, and patients with severe pneumonia. Patients were also divided into sub-groups according to the outcome: dead and survived.
RESULTS: Serum CXCL9, CXCL10, CXCL11, and CXCR3 levels were significantly higher in patients with severe COVID-19 than in those with non-severe COVID-19; were higher in both patient groups than in the control group; and were higher in patients who died than in those who survived. Lymphocyte counts, and fibrinogen and PaO2/FiO2 levels were significantly lower in patients with severe COVID-19 than in those with moderate disease. Patients with COVID-19 also had elevated neutrophil/lymphocyte ratios, neutrophil counts, and lactate dehydrogenase, C-reactive protein, D-dimer, and ferritin levels.
CONCLUSIONS: This study confirmed that CXCL9, CXCL10, CXCL11, and CXCR3 levels are associated with disease severity in patients with COVID-19. These laboratory parameters can help to estimate disease severity and predict outcomes, and are useful in clinical decision-making.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:56 |
|---|---|
| Enthalten in: |
Revista da Sociedade Brasileira de Medicina Tropical - 56(2023) vom: 24., Seite e01282023 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Çelik, Neslihan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CXCL9 protein, human |
|---|
| Anmerkungen: |
Date Completed 27.07.2023 Date Revised 29.07.2023 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1590/0037-8682-0128-2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359938760 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359938760 | ||
| 003 | DE-627 | ||
| 005 | 20231226081937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/0037-8682-0128-2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359938760 | ||
| 035 | |a (NLM)37493737 | ||
| 035 | |a (PII)S0037-86822023000100325 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Çelik, Neslihan |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The CXCL9/10/11-CXCR3 axis as a predictor of COVID-19 progression |b a prospective, case-control study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2023 | ||
| 500 | |a Date Revised 29.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This study examined the relationship between levels of the chemokines CXCL9, CXCL10, CXCL11, and CXCR3 and mortality in patients with COVID-19 | ||
| 520 | |a METHODS: A total of 71 patients hospitalized with COVID-19 and 35 health workers with no symptoms and negative SARS-CoV-2 PCR results were included in the study. CXCL9, CXCL10, CXCL11, and CXCR3 levels were measured in blood samples using enzyme-linked immunosorbent assays. Participants were divided into three groups: healthy individuals, patients with mild to moderate pneumonia, and patients with severe pneumonia. Patients were also divided into sub-groups according to the outcome: dead and survived | ||
| 520 | |a RESULTS: Serum CXCL9, CXCL10, CXCL11, and CXCR3 levels were significantly higher in patients with severe COVID-19 than in those with non-severe COVID-19; were higher in both patient groups than in the control group; and were higher in patients who died than in those who survived. Lymphocyte counts, and fibrinogen and PaO2/FiO2 levels were significantly lower in patients with severe COVID-19 than in those with moderate disease. Patients with COVID-19 also had elevated neutrophil/lymphocyte ratios, neutrophil counts, and lactate dehydrogenase, C-reactive protein, D-dimer, and ferritin levels | ||
| 520 | |a CONCLUSIONS: This study confirmed that CXCL9, CXCL10, CXCL11, and CXCR3 levels are associated with disease severity in patients with COVID-19. These laboratory parameters can help to estimate disease severity and predict outcomes, and are useful in clinical decision-making | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Chemokine CXCL10 |2 NLM | |
| 650 | 7 | |a Receptors, CXCR3 |2 NLM | |
| 650 | 7 | |a CXCL9 protein, human |2 NLM | |
| 650 | 7 | |a Chemokine CXCL9 |2 NLM | |
| 650 | 7 | |a CXCR3 protein, human |2 NLM | |
| 700 | 1 | |a Çelik, Onur |e verfasserin |4 aut | |
| 700 | 1 | |a Laloğlu, Esra |e verfasserin |4 aut | |
| 700 | 1 | |a Özkaya, Alev |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista da Sociedade Brasileira de Medicina Tropical |d 1993 |g 56(2023) vom: 24., Seite e01282023 |w (DE-627)NLM012655953 |x 1678-9849 |7 nnns |
| 773 | 1 | 8 | |g volume:56 |g year:2023 |g day:24 |g pages:e01282023 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1590/0037-8682-0128-2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 56 |j 2023 |b 24 |h e01282023 | ||